Drugs / xintilimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05215379 | Oct 2022 → Dec 2024 | rectal cancer | Changhai Hospital | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | xintilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05215379 ↗ |